​

Disseminated squamous cell carcinomas (SCCs) are traditionally considered void of actionable molecular targets, in contrast to adenocarcinomas, where an increasing number of targets are identified. SCC rarely undergo routine molecular testing and approved targeted therapies are rare in this population. The study investigated mutational landscape in SCC using comprehensive molecular and subsequent therapeutic implications. 

Between 2013 and 2023 patients with late-stage SCCs (head and neck cancer, non-small-cell lung cancer, cervical cancer, thymic carcinoma or unknown primary tumor) referred to a Phase I facility were included. In total, 189 patients with SCC were enrolled. Genomic profiles were obtained in 163 (86%). At least one actionable target was detected in 76 (47%). In total, 18 patients (11%) were treated with regimen matched to the genomic profile. In the treated group, 25% of the patients had either partial (>30% decrease in the sum of the target lesions) or complete response (disappearance of all target lesions). Furthermore, the study illustrated increasing targeted treatment opportunities for SCC during the last decade.

The study demonstrated increasing targeted treatment options for SCCs and high overall response rate (partial or complete response), thereby emphasizing the importance of genomic profiling.

See the presented poster​